Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial.

about

Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial.

Item

http://www.wikidata.org/entity/Q47140678

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Empagliflozin reduces albuminu ...... om the EMPA-REG OUTCOME trial.

@en

Empagliflozin reduces albuminu ...... om the EMPA-REG OUTCOME trial.

@nl

type

Item

label

Empagliflozin reduces albuminu ...... om the EMPA-REG OUTCOME trial.

@en

Empagliflozin reduces albuminu ...... om the EMPA-REG OUTCOME trial.

@nl

prefLabel

Empagliflozin reduces albuminu ...... om the EMPA-REG OUTCOME trial.

@en

Empagliflozin reduces albuminu ...... om the EMPA-REG OUTCOME trial.

@nl

P1476

Empagliflozin reduces albuminu ...... rom the EMPA-REG OUTCOME trial

@en

P2093

Frederik Persson

http://www.w3.org/2001/XMLSchema#string

Rikke Borg

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

Microalbuminuria: a parameter that has changed diabetes care.

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

P304

478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/ATM.2017.11.02

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Frederik Persson

R Borg

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29285511

http://www.w3.org/2001/XMLSchema#string

P932

5733313

http://www.w3.org/2001/XMLSchema#string